Ozempic & GLP-1 Drug Lawsuit

Did a GLP-1 Drug Cause Your Serious Injury?

Patients prescribed Ozempic, Wegovy, Mounjaro, Zepbound, and other GLP-1 drugs who developed severe gastroparesis, intestinal obstruction, ileus, or sudden vision loss may have a legal claim for compensation.

3,500+
Cases Pending in Federal MDL 3094 (Gastroparesis & Related Injuries)
Source: U.S. District Court, E.D. Pa., MDL 3094 docket, 2026
Get Your Case Review →

GLP-1 Drugs & Serious Injuries: What You Need to Know

GLP-1 receptor agonists, including Ozempic, Wegovy, and Rybelsus (Novo Nordisk) and Mounjaro, Zepbound, and Trulicity (Eli Lilly), have become some of the most widely prescribed medications in the United States for type 2 diabetes and weight loss. Tens of millions of Americans have taken these drugs.

Lawsuits allege that these medications can cause severe gastrointestinal injuries, including gastroparesis (stomach paralysis), intestinal obstruction, and ileus (paralysis of the intestinal muscles). Plaintiffs also report persistent vomiting, severe abdominal pain, dehydration, and significant weight loss requiring hospitalization.

In December 2025, a second federal MDL (MDL 3176) was established to consolidate claims that GLP-1 drugs can cause non-arteritic anterior ischemic optic neuropathy (NAION) - a sudden, often permanent form of vision loss. Both MDLs are proceeding before Judge Karen Marston in the Eastern District of Pennsylvania.

In January 2025, the FDA approved a label update for Ozempic adding a severe-gastroparesis caution. Plaintiffs allege that Novo Nordisk and Eli Lilly knew or should have known about these risks earlier and failed to adequately warn patients and prescribing physicians.

3,500+
Cases pending in MDL 3094 (gastroparesis and related injuries)
MDL docket, April 2026
MDL 3176
Second federal MDL for GLP-1 vision loss (NAION) cases
JPML, December 2025
2025
FDA-approved label update adding severe-gastroparesis caution to Ozempic
FDA, January 2025
Active
Litigation growing rapidly; cases being filed nationally
E.D. Pa., 2026
⏰ Act Promptly: Statutes of limitations for GLP-1 product liability claims vary by state and may run from the date of diagnosis or when the connection to the medication was discovered. Consult an attorney promptly to confirm your filing deadline.

Do You Qualify? Common Eligibility Criteria

Every case is unique and requires individual attorney review. Individuals who may have a viable GLP-1 drug claim typically meet criteria similar to the following:

✓ You May Qualify If You:

  • Were prescribed Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, Victoza, or Saxenda
  • Were diagnosed with gastroparesis (stomach paralysis) after starting a GLP-1 drug
  • Experienced intestinal obstruction or ileus requiring hospitalization
  • Were diagnosed with NAION (non-arteritic anterior ischemic optic neuropathy) or sudden vision loss
  • Required hospitalization, feeding tube, or surgery due to GI complications
  • Diagnosis occurred during GLP-1 use or within a reasonable period after
  • Within the applicable statute of limitations for your state

What Is Gastroparesis?

Gastroparesis is a condition in which the stomach cannot empty food normally due to impaired muscle function. Symptoms include severe nausea, vomiting, abdominal pain, bloating, early satiety, and unintended weight loss. Severe cases can require feeding tubes, surgical intervention, and lifelong dietary management. In lawsuits, plaintiffs allege that GLP-1 drugs caused prolonged or permanent gastroparesis that did not resolve after stopping the medication.

NAION Vision Loss

NAION is a sudden, painless loss of vision in one or both eyes caused by interrupted blood flow to the optic nerve. Research published in 2024 and 2025 suggested a possible association between GLP-1 drug use and elevated NAION risk, leading to the creation of MDL 3176 in December 2025. No U.S. label admission of NAION causation has been issued as of April 2026, but plaintiffs allege the manufacturers had knowledge of the risk.

Drugs Named in the Litigation

Claims typically involve semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda), and dulaglutide (Trulicity). Defendants include Novo Nordisk and Eli Lilly. Eligibility for the MDL depends on the specific drug used, the injury, and the timing.

GLP-1 Drug Case Review

Takes 2 minutes

Your SituationYour Details
Step 1 of 2: Your Situation

Why Choose UnitedClaimsBureau?

UCB connects injury victims with experienced mass tort attorneys at no upfront cost. Here is what to expect when you work with us.

Pharmaceutical Case Experience

Your information is forwarded to attorneys experienced in pharmaceutical product liability and MDL litigation.

Contingency Representation

All affiliated attorneys work on a contingency fee basis - attorney fees apply only if your case results in a recovery.*

Dedicated Case Support

A dedicated case specialist will guide you through every step, from initial inquiry through attorney connection.

Confidential & Secure

Your personal and medical information is handled with strict confidentiality and is never sold to third parties.

Frequently Asked Questions

What drugs are involved in the GLP-1 lawsuits?
The lawsuits involve GLP-1 receptor agonist drugs, including Ozempic, Wegovy, and Rybelsus (semaglutide, made by Novo Nordisk); Mounjaro and Zepbound (tirzepatide, made by Eli Lilly); Victoza and Saxenda (liraglutide, Novo Nordisk); and Trulicity (dulaglutide, Eli Lilly).
What injuries are alleged in the litigation?
The primary injuries alleged in MDL 3094 are gastroparesis (stomach paralysis), intestinal obstruction, and ileus. A separate MDL (3176), established in December 2025, covers cases of NAION-related sudden vision loss. Plaintiffs also allege severe persistent vomiting, malnutrition, and dehydration requiring hospitalization.
Did the manufacturers warn about gastroparesis?
In January 2025, the FDA approved a label update for Ozempic adding a caution about severe gastroparesis. Plaintiffs allege that Novo Nordisk and Eli Lilly had access to scientific data or adverse-event reports suggesting this risk earlier and failed to adequately warn patients and prescribing physicians - amounting to a failure to warn under product liability law.
Is there a class action or MDL?
There are two federal MDLs before Judge Karen Marston in the Eastern District of Pennsylvania. MDL 3094 consolidates gastroparesis, intestinal obstruction, and ileus claims (approximately 3,550 cases as of April 2026). MDL 3176, established in December 2025, consolidates NAION vision-loss claims.
How long do I need to have used the drug to qualify?
There is no strict minimum duration. Eligibility generally depends on the severity of the injury, the timing of the diagnosis relative to GLP-1 use, and the specific drug involved. An attorney can evaluate your specific history against current MDL criteria.
What if I took the drug for weight loss rather than diabetes?
Both indications are covered. Wegovy and Zepbound are FDA-approved specifically for chronic weight management, while Ozempic and Mounjaro are approved for type 2 diabetes but often prescribed off-label for weight loss. Eligibility focuses on the injury rather than the reason for the prescription.
How long do I have to file a lawsuit?
The statute of limitations for product liability claims varies by state - commonly 2 to 6 years from the date of diagnosis or from when you reasonably discovered the connection between the drug and the injury. Consult an attorney promptly to confirm your specific filing deadline.
How much does it cost to pursue a claim?
UnitedClaimsBureau works with attorneys on a contingency fee basis, meaning there are no upfront costs. Attorney fees are only paid if your case results in a recovery.*
What records should I gather?
Key records include: prescription history showing the GLP-1 drug, dates, and dosages; medical records of your diagnosis (endoscopy, gastric emptying study, imaging, ophthalmologic evaluation for NAION); hospitalization records; and any communications with your prescribing physician. Start gathering these as soon as possible.

You May Have a GLP-1 Drug Claim

If you or a loved one was diagnosed with gastroparesis, intestinal obstruction, or NAION vision loss after using Ozempic, Wegovy, Mounjaro, or another GLP-1 drug, find out in minutes - confidential, no obligation.

Start Your Case Review
Start Your Case Review